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Abstract We recently identified the cis-regulatory element and 
its specific nuclear binding factors for A~Z-prostaglandin (PG) 
J2-induced expression of the rat heme oxygenase, HO-I 
[Koizumi, T., Odani, N., Okuyama, T., Ichikawa, A. and 
Negishi, M. (1995) J. Biol. Chem. 270, in press]. Here we further 
examined the molecular mechanism underlying the /t~2-PGJ2- 
induced HO-1 gene expression. Protein kinase inhibitors, 2-amin- 
opurine and staurosporine, suppressed the AI2-PGJ2-induced 
HO-1 mRNA and the nuclear protein binding to the A12-PGJ2 - 
responsive cis-regulatory element in rat basophilic leukemia cells. 
Furthermore, the nuclear protein binding to the element was 
suppressed by in vitro phosphatase treatment of the nuclear pro- 
teins from A~2-PGJ2-treated cells. These findings suggest that 
A12-PGJ 2 induces the expression of the HO-I gene through phos- 
phorylation of the nuclear proteins which bind to the A~z-PGJ z- 
responsive lement. 
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1. Introduction 
Cyclopentenone prostaglandins (PGs), such as A~2-PGJ2 and 
PGA2, exert a variety of biological actions, including cessation 
of cell growth, cell differentiation and development [1]. The 
actions of cyclopentenone PGs are attributed to the synthesis 
of various proteins induced by them, such as heat shock pro- 
teins (HSPs) [2,3], y-glutamylcysteine synthetase [4], and colla- 
gen [5], gadd 153 [6], and heine oxygenase [7]. 
Heme oxygenase is one of the most prominent proteins in- 
duced by A~2-pGJ2, and it is a key enzyme in heme catabolism, 
oxygenizing heme to yield biliverdin, iron and carbon monoox- 
ide [8]. The biological functions of this enzyme are the produc- 
tion of biliverdin as a physiological ntioxidant and the conser- 
vation of the iron [9]. Furthermore, carbon monooxide pro- 
duced on the enzymatic degradation of heine has been sug- 
gested to function as a neural messenger [10]. Two isozymes of 
heine oxygenase, HO-1 and HO-2, have been identified [11]. 
HO-2 is constitutively expressed, while HO-1 is drastically in- 
duced in response to a variety of stresses, including heavy 
metals, heat shock and UV irradiation [12-14]. We previously 
found that A ~ 2-pGJ 2 preferentially induced the synthesis of HO- 
I in various cells involved in the reticulo-endothelial system, in 
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which active degradation of heme by HO-1 takes place during 
inflammation [7]. Furthermore, we identified the A~Z-PGJ2-spe - 
cific cis-regulatory element, the AL2-pGJ2-responsive element, 
located in the 5'-flanking region of HO-I gene, for AtZ-PGJ z- 
induced expression of the HO-1 gene, and two specific nuclear 
factors, the Al2-pGJ2-responsive factors, which bind to the ele- 
ment in response to A~2-PGJ2 [15], However, the molecular 
mechanisms for the AlZ-pGJz-induced nuclear factor binding to 
the element remain unclear. The DNA binding activity of nu- 
clear transcription factors has been shown to be modulated by 
phosphorylation [16]. We suggest here that the Al2-pGJ2-in - 
duced HO-1 gene expression is regulated through phosphoryla- 
tion of the A~2-pGJ:-responsive factors which bind to the A ~2- 
PGJ2-responsive element. 
2. Materials and methods 
2.1. Materials 
A~'-PGJ, was a generous gift from Teijin Ltd. (Tokyo, Japan). 
[y-32p]ATt~ (3,000 Ci/mmol) was obtained from Dupont-New England 
Nuclear (Boston, MA). 2-Aminopurine (2-AP) and staurosporine w re 
from Sigma (St. Louis, MO); calf intestinal phosphatase from Boehrin- 
ger-Mannheim (Mannheim, Germany); and sodium fluoride and so- 
dium vanadate from Wako Pure Chemical Industries Ltd. (Tokyo, 
Japan). 
Rat basophilic leukemia (RBL)-2H3 cells were obtained from the 
Japanese Cancer Research Bank (Tokyo, Japan). The cells were cul- 
tured in Dulbecco's modified Eagle's medium supplemented with 10% 
fetal bovine serum, 4 mM glutamine, 0.2 mg/ml streptomycin a d 100 
units/ml penicillin under humidified air containing 5% CO2 at 37°C. 
2.2. sSS-Labeling conditions and SDS-PAGE 
Cells cultured in 12-well plates (2 x l05 cells/well) were incubated for 
3 h with 0.4 ml of methionine-free Eagle's medium containing 
[~SS]methionine ( 10pCi/ml) and l 0% dialyzed fetal bovine serum. After 
incubation, the cells were washed with ice-cold phosphate-buffered 
saline, lysed and subjected to SDS-10%PAGE, as described previously 
[17]. 
2.3. Northern blots 
Total RNA from RBL-2H3 cells was isolated using an Isogen RNA 
isolation kit (Nippon-gene, Tokyo), and 5/zg of each RNA was sepa- 
rated by electrophoresis on a 1.5% agarose gel, transferred toa nylon 
membrane (Hybond-N, Amersham Corp.), and hybridized with a s:p_ 
labeled fragment, corresponding to exon 3 of the rat HO-I gene. Hy- 
bridization was carried out at 68°C in 6 x SSC, and the filter was 
washed at 68°C in 2 x SSC. The filter was autoradiographed with X-ray 
film (Fuji RX). The radioactivity was determined with a Fuji BAS 2000 
imaging analyzer (Fuji Film Co., Tokyo). 
2.4. Gel mobility shift assay 
A complementary pair of DNA fragments encoding region, -690 to 
-660, relative to the transcription start site, which contains the A ~2- 
PGJ2-responsive is-regulatory element, was synthesized with an ABI 
391 DNA synthesizer (Applied Biosystems Inc., CA), and then an- 
nealed as a probe. The fragment was radiolabeled atthe 5' ends with 
[?'-32p]ATP using 74 polynucleotide kinase. Nuclear extracts were pre- 
pared by detergent lysis method of Block et al. [18]. The nuclear extracts 
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(2/tg) were incubated with 2 pg of poly(dI-dC) and 1 ng of a 32p-labeled 
probe (10,000 cpm) for 30 min at 30°C in 25 mM HEPES-NaOH (pH 
7.9), containing 0.5 mM EDTA, 50 mM KCI, 10% glycerol, 0.5 mM 
dithiothreitol and 0.5 mM phenylmethylsulfonyl fluoride. The reaction 
mixtures were lectrophoresed on native 4% polyacrylamide g ls at 4°C 
at 150 V for 2 h in 50 mM Tris-HCl (pH 8.5), containing 380 mM 
glycine and 2 mM EDTA. The gels were dried on Whatman 3MM 
paper and then autoradiographed with X-ray film (Fuji RX). 
3. Results and discussion 
The purine analogue, 2-AE a broad spectrum protein kinase 
inhibitor, has been shown to inhibit various gene expression 
[19]. We examined the effect of 2-AP on A'2-PGJ2-induced syn- 
thesis of HO-1 in RBL-2H3 cells. As shown in Fig. 1, 2-AP 
treatment almost completely inhibited the synthesis of HO-1 
induced by /f2-PGJ2 without any alteration of basal protein 
synthesis, indicating that 2-AP specifically inhibited the /I '2- 
PGJ2-induced protein synthesis. In addition to HO-1, A~2-PGJ2 
induced the synthesis of HSP70, and the 2-AP treatment also 
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Fig. 1. Effect of 2-AP on the induction of HO-1 synthesis by A]Z-PGJ 2 
in RBL-2H3 cells. RBL-2H3 cells were incubated with the vehicle (-) 
or 3 mM 2-AP (+) for 3.5 h in the presence of[35S]methionine, and for 
the last 3 h were treated with (J) or without (C) 10/aM zI~2-PGJ> The 
cells were then lysed and subjected to SDS-10%PAGE, followed by 
fluorography as described in section 2. The positions of molecular 
weight markers are shown on the left. The arrows indicate the positions 
of HO-1 and HSP70. 
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Fig. 2. Effects of 2-AP and staurosporine on the A~Z-PGJ2-stimulated 
HO-1 mRNA induction and the binding of the A~2-PGJz-responsive 
factors to the A~2-PGJ:-responsive element. After cells had been incu- 
bated with the vehicle (N), 3 mM 2-AP (AP) or 100 nM staurosporine 
(ST) for 30 min, they were treated with (J) or without (C) 10/tM 
A~2-PGJ2 for 3 h (A) or 2 h (B). (A) Total cellular RNA was extracted 
and subjected toNorthern blot analysis as described insection 2. HO-1 
rnRNA values are expressed as fold of the untreated cell value. 
(B) Nuclear extract was prepared for the gel mobility shift assay using 
DNA fragment, including the A~Z-PGJ2-responsive el ment, as de- 
scribed in section 2. I and II represent the specific protein-DNA com- 
plexes. The results are representative of three independent experiments 
that yielded similar esults. 
completely inhibited the A~2-pGJ2-induced HSP70 synthesis 
(Fig. 1). We further examined the effects of protein kinase 
inhibitors on the A'LPGJ2-stimulated HO-1 mRNA induction. 
In addition to 2-AP, we used other inhibitor, staurosporine, 
which is an inhibitor for serine/threonine protein kinases, in- 
cluding protein kinase C [20]. As shown in Fig. 2A, 2-AP and 
staurosporine suppressed the ability of A'2-pGJz to stimulate 
HO-1 mRNA induction, indicating that the inhibition of the 
A'2-PGJ2-induced HO-I synthesis i due to suppression of the 
HO-1 gene expression. Recently, an element responsible for 
12-O-tetradecanoylphorbol-13-acetate was identified in the 
mouse HO-1 gene, suggesting involvement of protein kinase C 
in induction of the mouse HO-1 gene [21]. In RBL-2H3 cells, 
12-O-tetradecanoylphorbol-13-acetate ould not induce the 
HO-1 gene expression (data not shown). We recently demon- 
strated that the A'Z-PGJ2-induced HO-1 gene expression was 
mediated by the binding of nuclear proteins, the A'Z-PGJ2 -
responsive factors, to the A12-pGJ2-responsive c/s-regulatory 
element [15]. Thus, we examined the effects of these inhibitors 
on the A]2-pGJ2-stimulated nuclear protein binding to the ele- 
ment. As shown in Fig. 2B, /f2-PGJ 2 markedly induced two 
nuclear protein-DNA complexes, and 2-AP and staurosporine 
completely abolished the Al2-pGJ2-induced nuclear protein 
binding to the element. These results uggest that the 312-pGJ 2- 
induced nuclear protein binding to the element is regulated by 
phosphorylation. To assess phosphorylation f the A~2-PGJ2- 
responsive factors, we exposed anuclear extract from d~2-pGJ2- 
treated cells to calf intestinal phosphatase and examined the 
binding of the d12-pGJ2-responsive factors to the element. As 
shown in Fig. 3, phosphatase treatment completely inhibited 
the binding activity of the factors to the element, and this 
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Fig. 3. Effect of phosphatase treatment on the A~2-PGJ2-induced bind- 
ing of the A~2-PGJ2-responsive factors to the AILpGJ2-responsive ele- 
ment. After cells had been treated with (J) or without (C) 10 pM 
A~LPGJ2 for 2 h, nuclear extracts were prepared. The nuclear extracts 
were incubated with the vehicle (-), 0.5 unit of calf intestinal phosphat- 
ase (+), the phosphatase and 1 mM sodium fluoride (F), or the phos- 
phatase and 20/.tM sodium vanadate (V). After incubation, DNA 
binding activity to the fragment, including the AJ2-PGJ2-responsive el - 
ment, was measured in a gel mobility shift assay. I and II represent the 
specific protein-DNA complexes. The results are representative of
three independent experiments hat yielded similar results. 
inhibition was blocked by the addition of phosphatase inhib- 
itors, sodium fluoride and sodium vanadate, suggesting that the 
binding of the A~2-PGJ2-responsive factors to the element is 
regulated by phosphorylation f the factors or phosphorylation 
of a nuclear component(s) which regulates the binding of the 
factors to the element. 
These findings uggest that 3~2-pGJ 2stimulates phosphoryla- 
tion of the A~2-PGJ2-responsive factors, leading to the binding 
of the factors to the A~2-PGJ2-responsive element and subse- 
quent induction of HO-1 gene expression. In addition, we 
showed that A~2-PGJ2-induced HSP70 synthesis was also sensi- 
tive to the protein kinase inhibitor (Fig. 1). The A12-PGJ2-in - 
duced HSP70 synthesis has been shown to be mediated through 
binding of heat shock factors to heat shock element located in 
the 5'-flanking region of the HSP70 gene [22,23]. The A12-PGJ 2- 
induced binding of heat shock factors to heat shock element 
was also suppressed by 2-AP treatment in RBL-2H3 cells (data 
not shown). Thus, protein kinase(s) appears to be generally 
281 
involved in the A~2-PGJ2-induced gene expression through 
phosphorylation f the responsive transcription factors, includ- 
ing heat shock factors and the A12-pGJ2-responsive factors. 
HSP70 and HO-1 belong to a stress protein family. A variety 
of stress proteins, including HSPs, are induced by compounds 
or conditions that perturb nascent protein synthesis [24]. Con- 
cerning regulatory mechanism for stress protein induction, a 
cDNA for a novel serine/threonine kinase, Ern lp, has been 
recently isolated from yeast, and this kinase was shown to be 
essential for a set of specific stress gene expression induced by 
perturbation ofnascent protein synthesis [25,26]. The A 12-PGJ 2- 
induced HSP70 gene expression has been shown to require de 
novo protein synthesis [22,23]. The A12-PGJ2-induced HO-I 
gene expression also required de novo protein synthesis (data 
not shown). The requirement of de novo protein synthesis for 
the A~2-PGJ2-induced gene expression suggests that A~2-PGJ 2 
affects nascent protein synthesis, inducing expression of stress- 
related genes. Considering these findings, this type of protein 
kinase could be involved in the A~2-PGJ2-induced HO-1 gene 
expression. 
In summary, we report here that protein kinase is involved 
in the A~2-PGJ2-induced HO-I gene expression, and the site of 
action is on the A12-pGJ2-responsive factors which bind to the 
A~2-PGJ2-responsive el ment. This study will facilitate lucida- 
tion of the molecular mechanisms underlying the actions of 
cyclopentenone PGs. 
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